London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm not sure if VLG have anything unique here. Colgate seemed to be getting similar results:
https://www.nature.com/articles/s41415-020-2476-8
Interesting the space they give to what nobody seems interested in:
"The Company continues to await the publication of the peer-reviewed in vivo study carried out by Cardiff University, which was completed in April this year. Whilst the Board is disappointed that this has taken longer than expected to publish, and does acknowledge that the timing is outside the control of Cardiff University, it is hopeful the final publication will be available soon. Further, the Company notes the recent announcement made by Salisbury Hospital regarding specific mouth care guidance for patients with Covid-19. As well as regular toothbrushing, the guidance also suggests that both Dentyl Dual Action and Dentyl Fresh Protect should be used. The Company understands this guidance was based on research conducted by Doctors at Salisbury Hospital, as well as the in-vitro (lab based) results widely published by Cardiff University in November 2020."
First I'm just relieved that they mention it at all. If the results were bad and being quietly buried they wouldn't. Second, they mention their disappointment, and point the finger of blame - sort of. They're publicly kicking some hidden someone up the proverbial. If the truth is it does work that person/s will have many lives on their hands, and now has an interest in it not working: but the figures will be the figures and if you twisted them too far in a bad direction you could turn a nightmare into an utter disaster. The best thing for them is to get them out soon. I would be hopeful for this month.
Remember the in vitro results from 21st October last year:
"Today, the Company provides an update on the recently published[1] in-vitro results from a separate, independent laboratory study undertaken at Cardiff University by Dr Richard Stanton and his colleagues.
In their published in-vitro[2] study, scientists at Cardiff University concluded that Venture Life's two CPC based mouthwashes eradicated the SARS-CoV-2 (COVID-19) virus completely (>5log reduction, equivalent to 99.999%) within a 30 second exposure. The virus was supplied by Public Health England, unlike other similar studies reported in the media, which have not used the relevant COVID-19 virus, but a related strain of it.
Cardiff University went on to state that the 'exact formulation is also important'. Whilst the CPC technology in Venture Life's mouthwash proved highly effective in the in-vitro study, they also tested a third mouthwash, which also contained both CPC and another ingredient, yet this proved ineffective."
99.999% reduction with a 30 second in vitro exposure.
Yes, I know: throat, not nose (use Taffix), and lung (see SNG001 from Synairgen) - but gaining the body vital TIME. And the Salisbury docs agree.
Still gargling. Still well. And tripled my holding.
It'll be interesting to see ST's update in Investor's Chronicle when he's back in the New Year. Last updates on this were:
10/08/2021 (92p): Venture’s shares have doubled since I initiated coverage, at 45p, in my May 2019 Alpha Report, and offer 50 per cent potential upside to my 130p target price. Buy.
16/08/2021 (65p): In my view, there has been a massive overreaction to last week’s trading update – 2022 forecasts are in line with the expectations I outlined in last week’s article – and the share price fall is not only overdone, but is likely to prove a cracking buying opportunity. I am certainly not changing my 130p target price. Buy
Some of these tips seem to need some serious wealth warnings! 92p to 130p is 42% upside; currently it's down 62% from there - not great risk/reward. Loop-up was another dud.
At least the commercial property and mining tips are asset-backed and probably have some tailwinds behind them (recovery plays on NAV and commodity super-cycle).
Aquisitions?
SP needs to triple before any mention of an aquisition.
Jolly, what happened to you? You used to write some good informative posts until a couple of years ago when you had a spat with riddler. Now it's just 1 sentenced posts which are just, well, less informative.
Trading update refers to having liquidity to fund further acquisitions... are they delusional?
ST strike yet again
lol
…… and just to make matters worse, the CFO is leaving. Not a good sign. And it was stuck at the bottom of the RNS after the announcement of NED leaving as if to hide it.
Well you have to give it to the bod, selling at 90p in the placing. Well done.
I can see this going to 20p now. Downgrade in forecast will leave the company very close making a loss this year if it doesn’t make a loss. The credit facility will be used to maintain the company which of course will add to the capex.
Some of the themes that were referenced in the Company's Interim Results, announced on 23 September 2021, have continued. The integration of BBI Healthcare, the Company's largest ever acquisition, remains on track and the Directors are pleased with the progress that has been made. The Helsinn Integrative Care Portfolio, acquired in August this year, has also performed in line with management's expectations and is further evidence of the Company's skill in identifying and executing acquisitions well.
More specifically, through BBI Healthcare brands, evaluation is underway at both Savers and Co-op on Balance Activ. Also, given the success that Balance Active has had on the Amazon platform in the UK, plans are underway to launch the brand in Germany on Amazon, which is expected to take place in Q1 2022.
TU summary :We have no clue what is ahead... it is really bad now.
Now would be a good time to land the cardiff study (if positive).
moving on down
... on no news ;)
Sp moving up nicely :)
Jolly are you paid to put out your view ... or you must be the worst investor ever ..... 62P all day long
Yup jolly this is looking very good to me ... enjoing your speculators I am :)
Jolly… not at all perfect for me!
bit early?
Back in at 56p :)
Thank you 42trader, will have a look at the book!
Well done nutmegmilk on your profit here. I would suggest when you have winners you don’t sell all. Maybe deleverage by removing your initial stake then let the rest run. It is always a good idea to run your winners which then will turn an average year into a good year. Get the book called The art of execution. It’s a quick read but worth reading.
Unhooked I sold … probably too early but it suits me …. I hope the SP continues strong for all holders, glad to see it 43p was ridiculous!
Northern Trust hasve bought 5.84% of VLG:
HTtps://www.investegate.co.uk/venture-life-group--vlg-/rns/holding-s--in-company/202111010843048790Q/
Octopus Investments have bought more and raised their stake to 3.14% :
HTtps://www.investegate.co.uk/venture-life-group--vlg-/rns/holding-s--in-company/202111010844578792Q/
Cheers for the Downing update RedNinja. I note that Downing's report today also states:
"Venture Life is a leader in developing, manufacturing and commercialising products for the self-care market, which we have followed for some time through our ownership in other funds. We think the business has reached an interesting juncture with significant growth prospects.
Update to the investment case
Two immediately earning enhancing acquisitions
Revenues down over the year prior
Revolving Credit Facility of up to £50m
Supply prices have impacted H1 gross margin
Continued growth in core business (ex China and HSG)
Progress against investment case
Venture Life issued disappointing interims in September. As previously indicated, the drop off in hand sanitizer and international mouthwash sales resulted in reverse operational gearing due to lower volumes and a degree of mix affect. More positively, despite the large physical retail exposure the UK business held up robustly during the ongoing lockdown measures, hopefully demonstrating the more staple like characteristics of the underlying products.
In June, the company completed the acquisition of women’s health, hypoglycemia and energy management provider, BBI Healthcare. In August, the group completed a further acquisition which will be immediately earnings enhancing, Helsinn Integrative Care Portfolio (“Helsinn”). Helsinn generated £1.3 million of gross profit last year. Since this is an asset purchase only, all of this ought to drop through to the group’s earnings. Despite these acquisitions having a smaller effect on this financial year, we still think Venture Life presents good value on a worst-case basis. Taking pro-forma earnings from the recent M&A and writing down China Dentyl and hand sanitiser to zero, this is still a £10 million EBITDA business, with facility headroom and an operationally geared and capital light platform from which to continue consolidating."
Another strong day. Hope yr still invested Nutmeg!